1. Identification

Product identifier: Cerenia Injection

Other means of identification

Synonyms: CERENIA * Cerenia® (maropitant citrate) Injectable Solution * Cerenia® Injectable Solution * Maropitant Citrate Solution for Injection * Cerenia® Injection

Recommended use: Veterinary product used as Anti-emetic

Recommended restrictions: Not for human use

Manufacturer/Importer/Supplier/Distributor information

Company Name (US): Zoetis Inc.
10 Sylvan Way
Parsippany, New Jersey 07054 (USA)
1-866-531-8896

Rocky Mountain Poison and Drug Center
Product Support/Technical Services
Emergency telephone numbers

Company Name (EU): Zoetis Belgium S.A.
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Telephone: +32 10 808080

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: VMIPSrecords@zoetis.com

2. Hazard(s) identification

Physical hazards: Not classified.

Health hazards

- Serious eye damage/eye irritation: Category 2A
- Sensitization, skin: Category 1
- Specific target organ toxicity, repeated exposure: Category 2 (cardiovascular system, liver)

Environmental hazards

- Hazardous to the aquatic environment, acute hazard: Category 3
- Hazardous to the aquatic environment, long-term hazard: Category 3

OSHA defined hazards: Not classified.

Label elements

Signal word: Warning

Hazard statement: Causes serious eye irritation. May cause an allergic skin reaction. May cause damage to organs (cardiovascular system, liver) through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.
Precautionary statement

**Prevention**
Do not breathe mist or vapor. Wash thoroughly after handling. Contaminated work clothing must not be allowed out of the workplace. Avoid release to the environment. Wear eye protection/face protection. Wear protective gloves.

**Response**
Get medical advice/attention if you feel unwell. If on skin: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention. If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. Wash contaminated clothing before reuse.

**Storage**
Store away from incompatible materials.

**Disposal**
Dispose of contents/container in accordance with local/regional/national/international regulations.

**Hazard(s) not otherwise classified (HNOC)**
None known.

**Supplemental information**
Based on findings in animal studies, this compound may cause rare but potentially serious cardiac effects in human clinical use. Sulfobutylether b-cyclodextrin sodium (SBECD) has been associated with toxic effects in the kidney.

### 3. Composition/information on ingredients

#### Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common name and synonyms</th>
<th>CAS number</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfobutylether b-cyclodextrin sodium (SBECD)</td>
<td>7585-39-9</td>
<td>&lt;10</td>
<td></td>
</tr>
<tr>
<td>Maropitant Citrate Salt, Monohydrate</td>
<td>359875-09-5</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>m-Cresol</td>
<td>108-39-4</td>
<td>&lt;0.5</td>
<td></td>
</tr>
</tbody>
</table>

**Composition comments**
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

### 4. First-aid measures

#### Inhalation
Move to fresh air. Call a physician if symptoms develop or persist. If breathing is difficult, trained personnel should give oxygen.

#### Skin contact
Remove contaminated clothing immediately and wash skin with soap and water. Get medical attention if irritation develops and persists. In case of eczema or other skin disorders: Seek medical attention and take along these instructions. Wash contaminated clothing before reuse.

#### Eye contact
Immediately flush eyes with plenty of water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Get medical attention if irritation develops and persists.

#### Ingestion
Rinse mouth. Call a physician or poison control center immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconscious person.

#### Most important symptoms/effects, acute and delayed
Severe eye irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. Mild skin irritation. May cause an allergic skin reaction. Dermatitis. Rash. Prolonged exposure may cause chronic effects.

#### Indication of immediate medical attention and special treatment needed
Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed.

#### General information
For personal protection, see section 8 of the SDS. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Wash contaminated clothing before reuse.

### 5. Fire-fighting measures

#### Suitable extinguishing media
Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

#### Unsuitable extinguishing media
Do not use water jet as an extinguisher, as this will spread the fire.

#### Specific hazards arising from the chemical
During fire, gases hazardous to health may be formed.

#### Special protective equipment and precautions for firefighters
Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

#### Fire fighting equipment/instructions
Move containers from fire area if you can do so without risk.

#### Specific methods
Use standard firefighting procedures and consider the hazards of other involved materials.

#### General fire hazards
No unusual fire or explosion hazards noted.
6. Accidental release measures

Personal precautions, protective equipment and emergency procedures
Keep unnecessary personnel away. Ensure adequate ventilation. Wear appropriate protective equipment and clothing during clean-up. Avoid breathing mist or vapor. Avoid contact with eyes, skin, and clothing. Ventilate the contaminated area. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up
Wear appropriate protective equipment and clothing during clean-up. Ensure adequate ventilation. Prevent product from entering drains.

Large Spills: Stop the flow of material, if this is without risk. Absorb in vermiculite, dry sand or earth and place into containers. Clean surface thoroughly to remove residual contamination.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS.

Environmental precautions
Avoid release to the environment. Inform appropriate managerial or supervisory personnel of all environmental releases. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling
Ensure adequate ventilation. Avoid contact with eyes, skin, and clothing. Avoid breathing mist or vapor. Avoid accidental injection. Avoid prolonged exposure. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. When using, do not eat, drink or smoke. Wash thoroughly after handling. Avoid release to the environment.

Conditions for safe storage, including any incompatibilities
Keep away from heat, sparks and open flame. Store below 30°C Protect from light and freezing. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits
The following constituents are the only constituents of the product which have a PEL, TLV or other recommended exposure limit. At this time, the other constituents have no known exposure limits.

Zoetis Components | Type | Value
--- | --- | ---
Maropitant Citrate Salt, Monohydrate (CAS 359875-09-5) | TWA | 20 µg/m³
Sulfobutylether b-cyclodextrin sodium (SBEC) (CAS 7585-39-9) | TWA | 3000 µg/m³

**US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)**

<table>
<thead>
<tr>
<th>Components</th>
<th>Type</th>
<th>Value</th>
</tr>
</thead>
</table>
m-Cresol (CAS 108-39-4) | PEL | 22 mg/m³ 5 ppm |

**US. ACGIH Threshold Limit Values**

<table>
<thead>
<tr>
<th>Components</th>
<th>Type</th>
<th>Value</th>
<th>Form</th>
</tr>
</thead>
</table>
m-Cresol (CAS 108-39-4) | TWA | 20 mg/m³ | Inhalable fraction and vapor. |

**US. NIOSH: Pocket Guide to Chemical Hazards**

<table>
<thead>
<tr>
<th>Components</th>
<th>Type</th>
<th>Value</th>
</tr>
</thead>
</table>
m-Cresol (CAS 108-39-4) | TWA | 10 mg/m³ 2.3 ppm |

**Biological limit values**
No biological exposure limits noted for the ingredient(s).

**Exposure guidelines**
**US - California OELs: Skin designation**
m-Cresol (CAS 108-39-4) Can be absorbed through the skin.
US - Minnesota Haz Subs: Skin designation applies

US - Tennessee OELs: Skin designation
m-Cresol (CAS 108-39-4) Can be absorbed through the skin.

US ACGIH Threshold Limit Values: Skin designation
m-Cresol (CAS 108-39-4) Danger of cutaneous absorption

US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)
m-Cresol (CAS 108-39-4) Can be absorbed through the skin.

Control banding approach Not available.
Appropriate engineering controls Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment
Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection
Hand protection Wear suitable gloves. Wear impervious gloves if skin contact is possible.
Other Wear suitable protective clothing. Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection No personal respiratory protective equipment normally required. In case of insufficient ventilation, wear suitable respiratory equipment. If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn.

Thermal hazards Not applicable.

General hygiene considerations Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. Contaminated work clothing should not be allowed out of the workplace.

9. Physical and chemical properties
Appearance Aqueous solution
Physical state Liquid.
Form Liquid.
Color Clear, colorless to pale yellow
Odor Not available.
Odor threshold Not available.
P pH Not available.
Melting point/freezing point Not available.
Initial boiling point and boiling range Not available.
Flash point Not available.
Evaporation rate Not available.
Flammability (solid, gas) Not applicable.
Upper/lower flammability or explosive limits
Explosive limit - lower (%) Not available.
Explosive limit - upper (%) Not available.
Vapor pressure Not available.
Vapor density Not available.
Relative density Not available.
Solubility(ies)
Solubility (water) Not available.
Partition coefficient (n-octanol/water) Not available.

Material name: Cerenia Injection
Version #: 02 Revision date: 03-24-2022 Issue date: 04-19-2017 SDS US
4 / 10
10. Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous reactions No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Heat, flames and sparks. High temperatures.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition products Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

11. Toxicological information

Information on likely routes of exposure

Inhalation May cause damage to organs through prolonged or repeated exposure by inhalation.

Skin contact May cause an allergic skin reaction.

Maropitant Citrate Salt, Monohydrate Species: Rabbit Severity: Non-irritating

Sulfobutylether b-cyclodextrin sodium (SBEC) Species: Rabbit Severity: Non-irritating

m-Cresol Species: Rabbit Severity: Severe

Eye contact Causes serious eye irritation.

Sulfobutylether b-cyclodextrin sodium (SBEC) Species: Rabbit Severity: Non-irritating

Maropitant Citrate Salt, Monohydrate Species: Rabbit Severity: Severe

m-Cresol Species: Rabbit Severity: Severe

Ingestion May cause discomfort if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics Severe eye irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. Mild skin irritation. May cause an allergic skin reaction. Dermatitis. Rash.

Information on toxicological effects

Acute toxicity Not acutely toxic

Components Species Test Results

Maropitant Citrate Salt, Monohydrate (CAS 359875-09-5)

Acute Dermal

LD50 Rat > 2000 mg/kg

Oral

LDmin. Rat 1000 mg/kg (Maropitant methanesulfonate salt)
<table>
<thead>
<tr>
<th>Components</th>
<th>Species</th>
<th>Test Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subchronic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>Dog</td>
<td>5 mg/kg/day, 3 months [Target organ(s): Cardiovascular system (Maropitant methanesulfonate salt)]</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>5 mg/kg/day, 3 months [Target organ(s): Liver (Maropitant methanesulfonate salt)]</td>
</tr>
<tr>
<td>m-Cresol (CAS 108-39-4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acute</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50</td>
<td>Rabbit</td>
<td>2050 mg/kg</td>
</tr>
<tr>
<td><strong>Inhalation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LC50</td>
<td></td>
<td>58 mg/m3, 8 Hours</td>
</tr>
<tr>
<td><strong>Oral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50</td>
<td>Rat</td>
<td>242 mg/kg</td>
</tr>
<tr>
<td><strong>Sulfobutylether b-cyclodextrin sodium (SBEDC) (CAS 7585-39-9)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acute</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50</td>
<td>Rat/Mouse</td>
<td>&gt; 2000 mg/kg</td>
</tr>
<tr>
<td><strong>Oral</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD50</td>
<td>Rat</td>
<td>&gt; 2000 mg/kg</td>
</tr>
<tr>
<td><strong>Chronic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOAEL</td>
<td>Dog</td>
<td>600 mg/kg/day, 6 months Kidney</td>
</tr>
<tr>
<td></td>
<td></td>
<td>120 mg/kg/day, 1 months Kidney</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>600 mg/kg/day, 6 months Kidney Liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td>160 mg/kg/day, 1 months Kidney</td>
</tr>
<tr>
<td>Prolonged skin contact may cause temporary irritation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Corrosivity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maropitant Citrate Salt, Monohydrate</td>
<td>Species: Rabbit Severity: Non-irritating</td>
<td></td>
</tr>
<tr>
<td><strong>Serious eye damage/eye irritation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Causes serious eye irritation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Eye Contact</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfobutylether b-cyclodextrin sodium (SBEDC)</td>
<td>Species: Rabbit Severity: Non-irritating</td>
<td></td>
</tr>
<tr>
<td>Maropitant Citrate Salt, Monohydrate</td>
<td>Species: Rabbit Severity: Severe</td>
<td></td>
</tr>
<tr>
<td>m-Cresol</td>
<td>Species: Rabbit Severity: Severe</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory or skin sensitization</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory sensitization</strong></td>
<td>Not a respiratory sensitizer.</td>
<td></td>
</tr>
<tr>
<td><strong>Skin sensitization</strong></td>
<td>May cause an allergic skin reaction.</td>
<td></td>
</tr>
<tr>
<td>Skin sensitization</td>
<td>Maropitant Citrate Salt, Monohydrate GPMT Species: Guinea Pig Severity: Negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sulfobutylether b-cyclodextrin sodium (SBEDC) Species: Guinea Pig Severity: Positive</td>
<td></td>
</tr>
</tbody>
</table>
Germ cell mutagenicity

No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.

**Mutagenicity**

- **Sulfobutylether b-cyclodextrin sodium (SBEC)**
  - Bacterial Mutagenicity (Ames)
  - Result: Negative
  - Species: Salmonella , E. coli
  - In Vitro Chromosome Aberration
  - Result: Negative
  - Species: Human Lymphocytes
  - In Vivo Micronucleus
  - Result: Negative
  - Species: Mouse Bone Marrow
  - Mammalian Cell Mutagenicity
  - Result: Negative
  - Species: Chinese Hamster Ovary (CHO) cells HGPRT

- **Maropitant Citrate Salt, Monohydrate**
  - Result: Negative (In vitro, in vivo - Maropitant methanesulfonate salt)

**Carcinogenicity**

This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

- **IARC Monographs. Overall Evaluation of Carcinogenicity**
  - Not listed.
  - Not listed.
- **US. National Toxicology Program (NTP) Report on Carcinogens**
  - Not listed.

**Reproductive toxicity**

This product is not expected to cause reproductive or developmental effects. Based on available data, the classification criteria are not met.

- **Developmental effects**
  - **Maropitant Citrate Salt, Monohydrate**
    - 150 mg/kg/day Embryo / Fetal Development, Not teratogenic
    - Result: NOEL
    - Species: Rat
  - **Sulfobutylether b-cyclodextrin sodium (SBEC)**
    - 1500 mg/kg/day Embryo / Fetal Development, Not Teratogenic
    - Result: NOAEL
    - Species: Rabbit
    - Organ: Intravenous
    - 1500 mg/kg/day Fertility and Embryonic Development, No effects at maximum dose
    - Result: NOAEL
    - Species: Rat
    - Organ: Intravenous
    - 600 mg/kg/day Prenatal & Postnatal Development, Maternal Toxicity
    - Result: NOAEL
    - Species: Rat
    - Organ: Intravenous

- **Specific target organ toxicity - single exposure**
  - Not classified.

- **Specific target organ toxicity - repeated exposure**
  - May cause damage to organs (cardiovascular system, liver) through prolonged or repeated exposure.

- **Aspiration hazard**
  - Not an aspiration hazard.

- **Chronic effects**
  - May cause damage to organs through prolonged or repeated exposure. Prolonged inhalation may be harmful.
Further information

Based on findings in animal studies, this compound may cause rare but potentially serious cardiac effects in human clinical use. Sulfobutylether b-cyclodextrin sodium (SBECID) has been associated with toxic effects in the kidney.

12. Ecological information

Ecotoxicity

Harmful to aquatic life with long lasting effects. Avoid release to the environment.

<table>
<thead>
<tr>
<th>Components</th>
<th>Species</th>
<th>Test Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maropitant Citrate Salt, Monohydrate (CAS 359875-09-5)</td>
<td>Red Algae</td>
<td>IC50 0.23 mg/l, 7 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NOEC 0.082 mg/l, 7 days</td>
</tr>
<tr>
<td>Crustacea</td>
<td>Daphnia magna (Water Flea)</td>
<td>EC50 0.6 mg/l, 1.25 hours</td>
</tr>
<tr>
<td></td>
<td>Mysisopsis bahia (Mysid Shrimp)</td>
<td>LC50 0.68 mg/l, 48 hours</td>
</tr>
<tr>
<td></td>
<td>Daphnia magna (Water Flea)</td>
<td>NOEC 0.31 mg/l, 1.25 hours</td>
</tr>
<tr>
<td></td>
<td>Mysisopsis bahia (Mysid Shrimp)</td>
<td>0.302 mg/l, 48 hours</td>
</tr>
<tr>
<td>Fish</td>
<td>Cyprinodon variegatus (Sheepshead Minnow)</td>
<td>LC50 0.68 mg/l, 48 hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NOEC 0.302 mg/l, 48 hours</td>
</tr>
<tr>
<td>m-Cresol (CAS 108-39-4)</td>
<td>Scud (Gammarus fasciatus)</td>
<td>EC50 7 mg/l, 48 hours</td>
</tr>
<tr>
<td>Crustacea</td>
<td>Scud (Gammarus fasciatus)</td>
<td>EC50 7 mg/l, 48 hours</td>
</tr>
<tr>
<td>Fish</td>
<td>Rainbow trout, donaldson trout (Oncorhynchus mykiss)</td>
<td>LC50 8.9 mg/l, 96 hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NOEC 8.9 mg/l, 96 hours</td>
</tr>
<tr>
<td>Sulfobutylether b-cyclodextrin sodium (SBECID) (CAS 7585-39-9)</td>
<td>Green algae</td>
<td>IC50 &gt; 100 mg/L, Hours</td>
</tr>
<tr>
<td>Crustacea</td>
<td>Daphnia magna (Water Flea)</td>
<td>EC50 &gt; 96 mg/L, 48 Hours</td>
</tr>
<tr>
<td>Fish</td>
<td>Oncorhynchus mykiss (Rainbow Trout)</td>
<td>LC50 &gt; 220 mg/L, 96 Hours</td>
</tr>
</tbody>
</table>

Persistence and degradability

No data is available on the degradability of this product.

Bioaccumulative potential

See below

Partition coefficient n-octanol / water (log Kow)
Maropitant Citrate Salt, Monohydrate 5.12, (+/- 0.01)

Mobility in soil

No data available.

Adsorption

Soil/sediment sorption - log Koc
Maropitant Citrate Salt, Monohydrate 4.16, (estimated)

Other adverse effects

No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions

Avoid release to the environment. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international regulations.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste disposal company.
Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner.

Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

DOT
Not regulated as dangerous goods.

IATA
Not regulated as dangerous goods.

IMDG
Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not established.

15. Regulatory information

US federal regulations
This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)
TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)
Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

SARA 304 Emergency release notification
Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)
Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)
SARA 302 Extremely hazardous substance
Not listed.

SARA 311/312 Hazardous chemical
Yes

Classified hazard categories
- Serious eye damage or eye irritation
- Respiratory or skin sensitization
- Specific target organ toxicity (single or repeated exposure)

SARA 313 (TRI reporting)
Not regulated.

Other federal regulations
Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List
m-Cresol (CAS 108-39-4)
Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)
Not regulated.

Safe Drinking Water Act (SDWA)
FEMA Priority Substances Respiratory Health and Safety in the Flavor Manufacturing Workplace
m-Cresol (CAS 108-39-4) Low priority

US state regulations
California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

US. California. Candidate Chemicals List. Safer Consumer Products Regulations (Cal. Code Regs, tit. 22, 69502.3, subd. (a))
m-Cresol (CAS 108-39-4)

International Inventories

<table>
<thead>
<tr>
<th>Country(s) or region</th>
<th>Inventory name</th>
<th>On inventory (yes/no)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>Australian Inventory of Industrial Chemicals (AICIS)</td>
<td>No</td>
</tr>
<tr>
<td>Canada</td>
<td>Domestic Substances List (DSL)</td>
<td>No</td>
</tr>
</tbody>
</table>

Material name: Cerenia Injection
Version #: 02 Revision date: 03-24-2022 Issue date: 04-19-2017

SDS US
9 / 10
<table>
<thead>
<tr>
<th>Country(s) or region</th>
<th>Inventory name</th>
<th>On inventory (yes/no)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td>Non-Domestic Substances List (NDSL)</td>
<td>No</td>
</tr>
<tr>
<td>China</td>
<td>Inventory of Existing Chemical Substances in China (IECSC)</td>
<td>No</td>
</tr>
<tr>
<td>Europe</td>
<td>European Inventory of Existing Commercial Chemical Substances (EINECS)</td>
<td>No</td>
</tr>
<tr>
<td>Europe</td>
<td>European List of Notified Chemical Substances (ELINCS)</td>
<td>No</td>
</tr>
<tr>
<td>Japan</td>
<td>Inventory of Existing and New Chemical Substances (ENCS)</td>
<td>No</td>
</tr>
<tr>
<td>Korea</td>
<td>Existing Chemicals List (ECL)</td>
<td>No</td>
</tr>
<tr>
<td>New Zealand</td>
<td>New Zealand Inventory</td>
<td>No</td>
</tr>
<tr>
<td>Philippines</td>
<td>Philippine Inventory of Chemicals and Chemical Substances (PICCS)</td>
<td>No</td>
</tr>
<tr>
<td>Taiwan</td>
<td>Taiwan Chemical Substance Inventory (TCSI)</td>
<td>No</td>
</tr>
<tr>
<td>United States &amp; Puerto Rico</td>
<td>Toxic Substances Control Act (TSCA) Inventory</td>
<td>No</td>
</tr>
</tbody>
</table>

*A “Yes” indicates that all components of this product comply with the inventory requirements administered by the governing country(s). A “No” indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

<table>
<thead>
<tr>
<th>Issue date</th>
<th>04-19-2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision date</td>
<td>03-24-2022</td>
</tr>
<tr>
<td>Version #</td>
<td>02</td>
</tr>
</tbody>
</table>

Disclaimer: Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently available.

Revision information:
- Identification: Recommended restrictions
- Composition / Information on Ingredients: Disclosure Overrides
- Composition/information on ingredients: Component information
- First-aid measures: Ingestion
- Accidental release measures: Methods and materials for containment and cleaning up
- Handling and storage: Conditions for safe storage, including any incompatibilities
- Toxicological information: Acute toxicity
- Toxicological information: Reproductivity
- Toxicological information: Ingestion
- Ecological information: Bioaccumulative potential
- Disposal considerations: Disposal instructions
- GHS: Classification